Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma

Clin Lung Cancer. 2020 Mar;21(2):e65-e73. doi: 10.1016/j.cllc.2019.11.001. Epub 2019 Nov 21.
No abstract available

Keywords: Guillain-Barré syndrome (GBS); Immune-related adverse events; Immunotherapy; Lung cancer; Tumor immune microenvironment.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / pathology
  • Aged, 80 and over
  • Antineoplastic Agents, Immunological / adverse effects*
  • Guillain-Barre Syndrome / chemically induced
  • Guillain-Barre Syndrome / immunology
  • Guillain-Barre Syndrome / pathology*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Nivolumab / adverse effects*
  • Tumor Microenvironment / immunology*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab